IRCT20151227025726N14
Recruiting
Phase 3
Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19 pneumonia.
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 84
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Laboratory confirmed COVID\-19 with RT\-PCR
- •Age over 18 years old
- •Oxygen saturation \< 93%
- •Fever more than 72 hours before admission
- •Bilateral pulmonary infiltration
Exclusion Criteria
- •Chronic kidney Disease
- •Acute kidney Injury
- •Pregnancy or breastfeeding
- •Drug allergy history
- •Chronic liver disease
- •Mild phase of COVID\-19
- •Critical phase of COVID\-19
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
Recruiting
Phase 3
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126
Recruiting
Phase 2
Effectiveness of favipiravir in comparison with Tenofovir Alafenamid in patients with COVID-19COVID-19.COVID-19U07.1IRCT20150808023559N23Ardabil University of Medical Sciences100
Recruiting
Phase 3
The therapeutic effect of Favipiravir in COVID-19 patientsIRCT20211004052664N1Shahid Beheshti University of Medical Sciences80
Completed
Not Applicable
The Real-world Clinical Outcomes of Favipiravir Treatment in Mild to Moderate COVID-19 Patients in Single Outpatient Visit Followed by Home Isolation: a Multicenter, case-control StudyTCTR20221113004Chulabhorn Royal Academy1,037